Free Trial
NASDAQ:VIVS

VivoSim Labs Q1 2027 Earnings Results & Report

VivoSim Labs logo
$0.18 0.00 (-0.61%)
As of 11:20 AM Eastern
This is a fair market value price provided by Massive. Learn more.

VivoSim Labs reported Q1 2027 earnings on August 12, 2026. The company reported EPS of -$0.25, while revenue was $0.02 million.

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
After Market Closes

VivoSim Labs EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

VivoSim Labs Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

VivoSim Labs Q1 2027 Earnings FAQ

VivoSim Labs (NASDAQ:VIVS) reported earnings of -$0.25 per share for Q1 2027. The report was announced on Wednesday, August 12, 2026.

VivoSim Labs reported revenue of $0.02 million for Q1 2027.

VivoSim Labs Earnings Headlines

Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider sources say Elon Musk is developing a breakthrough technology he describes as '10x bigger than the largest product in history.' Nvidia's CEO has called it 'the next biggest opportunity after AI,' with potential lifetime sales reaching $20 trillion. A launch date of July 22nd is on the radar for early investors positioning ahead of the announcement.tc pixel
Analyzing iSpecimen (NASDAQ:ISPC) & VivoSim Labs (NASDAQ:VIVS)
See More VivoSim Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VivoSim Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VivoSim Labs and other key companies, straight to your email.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

View VivoSim Labs Profile